XBI241011C99000
- 0.12
- -0.32-72.73%
SPDR S&P Biotech ETF Newsroom
AbbVie Snaps Six Days of Losses, Trades in the Green
Why Recursion Is Getting Love as an AI and Drug Discovery Top Pick
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Insmed Analyst Ratings
(EXAS) - Analyzing Exact Sciences's Short Interest
AbbVie's Options: A Look at What the Big Money Is Thinking
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Viking Therapeutics Analyst Ratings
Gilead To Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline And HIV Leadership At IDWeek 2024
Nurix Therapeutics Will Present Preclinical Data From NX-5948, Currently In Phase 1b For B-Cell Malignancies And In IND-Enabling Studies For Autoimmune Disease, And GS-6791/NX-0479 In Collaboration With Gilead Sciences And Also In IND-enabling...
Arcus a New Overweight at Wells Fargo on Potential of Casdatifan in Kidney Cancer
Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting
Obesity Drug Coverage Could Boost Spending By $35B Through 2034
Viking Therapeutics Unusual Options Activity
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
AbbVie Analyst Ratings
Gilead Upgraded to Overweight by Wells Fargo, PrEP Launch Cited
U.S. Supreme Court Declines To Review Rulings That Invalidate United Therapeutics' Patent; Decisions That Liquidia Does Not Infringe Any Valid Claims Of The Three Patents Originally Asserted By United Therapeutics Are Now Final And Not Subject To...